CRM
59
4
VMC
57
3
KR
50
10
NVDA
60
-5
VZ
25
-2
OXY
41
4
CMA
39
3
KHC
29
2
NFLX
69
5
HAS
49
3
CAG
39
5
BAX
41
3
CA
40
4
XYL
43
-4
FLS
50
-3
FRT
38
-3
BRK.B
42
2
FE
41
2
ROK
43
-4
HBI
37
7
CRM
59
4
VMC
57
3
KR
50
10
NVDA
60
-5
VZ
25
-2
OXY
41
4
CMA
39
3
KHC
29
2
NFLX
69
5
HAS
49
3
CAG
39
5
BAX
41
3
CA
40
4
XYL
43
-4
FLS
50
-3
FRT
38
-3
BRK.B
42
2
FE
41
2
ROK
43
-4
HBI
37
7
Financhill
Back

Avalo Therapeutics 10K Form

Sell
29

AVTX
Avalo Therapeutics

Last Price:
13.38
Seasonality Move:
-7.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AVTX News And Ratings

See the #1 stock for the next 7 days that we like better than AVTX

AVTX Financial Statistics

Sales & Book Value

Annual Sales: $1.92M
Cash Flow: $-6.2M
Price / Cash Flow: 0
Annual Sales: $-108.83
Price / Book: 0

Profitability

EPS (TTM): -319.18780
Net Income (TTM): $-142.88M
Gross Margin: $640K
Return on Equity: 0%
Return on Assets: 0%

Avalo Therapeutics Earnings Forecast

Key Avalo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 9 years for AVTX is 33.26%.
  • The Selling, General & Administrative Expenses for AVTX have been equal to 535.34% of Gross Profit Margin.
  • The Research & Development expenses have been 716.42% of Revenue.
  • The Interest Expense is -10.83% of Operating Income.
  • The Net Earning history of AVTX is -1,639.50% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Avalo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AVTX
Website: avalotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AVTX Technical Analysis vs Fundamental Analysis

Sell
29
Avalo Therapeutics (AVTX) is a Sell

Is Avalo Therapeutics a Buy or a Sell?